9 0 4 9 6
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 2.6 Breast Cancer (Dove Med Press)
- 3.9 Clin Epidemiol
- 3.3 Cancer Manag Res
- 3.9 Infect Drug Resist
- 3.6 Clin Interv Aging
- 4.8 Drug Des Dev Ther
- 2.8 Int J Chronic Obstr
- 8.0 Int J Nanomed
- 2.3 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 4.0 OncoTargets Ther
- 2.2 Patient Prefer Adher
- 2.8 Ther Clin Risk Manag
- 2.7 J Pain Res
- 3.3 Diabet Metab Synd Ob
- 4.3 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.9 Pharmgenomics Pers Med
- 3.5 Risk Manag Healthc Policy
- 4.5 J Inflamm Res
- 2.3 Int J Gen Med
- 4.1 J Hepatocell Carcinoma
- 3.2 J Asthma Allergy
- 2.3 Clin Cosmet Investig Dermatol
- 3.3 J Multidiscip Healthc
已发表论文
康柏西普 (Conbercept) 在新生血管性老年化黄斑变性治疗中的表现
Authors Lu XM, Sun XD
Published Date April 2015 Volume 2015:9 Pages 2311—2320
DOI http://dx.doi.org/10.2147/DDDT.S67536
Received 12 December 2014, Accepted 4 February 2015, Published 22 April 2015
Abstract: In developed countries, age-related macular degeneration (AMD) is the
leading cause of irreversible blindness in individuals over the age of 65
years. Vascular endothelial growth factor (VEGF) plays a vital role in the
formation of neovascular AMD. VEGF regulates angiogenesis, enhances vascular
permeability, and drives the formation of choroidal neovascularization. As a
result of the introduction of anti-VEGF drugs, the incidence of blindness from
neovascular AMD has greatly reduced. Anti-VEGF drugs are used as a first-line
treatment for neovascular AMD. The most recent anti-VEGF drug is conbercept,
also named KH902, which was approved for the treatment of neovascular AMD by
the China Food and Drug Administration in December 2013. In this review, recent
clinical information regarding the use of conbercept to treat neovascular AMD
is summarized. Conbercept is a soluble receptor decoy that blocks all isoforms
of VEGF-A, VEGF-B, VEGF-C, and PlGF, which has a high binding affinity to VEGF
and a long half-life in vitreous. Preclinical studies have demonstrated its
anti-angiogenesis activity in both ocular neovascular disease models and tumor
models. Clinical trials of conbercept have shown its superior efficacy and
safety. Patients respond well even with 3-month treatment intervals following
loading doses once a month for 3 months. The potential therapeutic effect of
conbercept on the treatment of polypoidal choroidal vasculopathy, a special
type of neovascular AMD, is also promising. In summary, conbercept is a new
treatment option for ophthalmologists and their patients and may help address
the limitations of current anti-VEGF drugs.
Keywords: conbercept, KH902, age-related macular degeneration, vascular endothelial growth factor, neovascularization
Keywords: conbercept, KH902, age-related macular degeneration, vascular endothelial growth factor, neovascularization
